CY1123238T1 - Συνδυασμος antiστροφων αγωνιστων του υποδοχεα της ισταμινης-3 με αναστολεις της ακετυλοχολινεστερασης - Google Patents
Συνδυασμος antiστροφων αγωνιστων του υποδοχεα της ισταμινης-3 με αναστολεις της ακετυλοχολινεστερασηςInfo
- Publication number
- CY1123238T1 CY1123238T1 CY20201100725T CY201100725T CY1123238T1 CY 1123238 T1 CY1123238 T1 CY 1123238T1 CY 20201100725 T CY20201100725 T CY 20201100725T CY 201100725 T CY201100725 T CY 201100725T CY 1123238 T1 CY1123238 T1 CY 1123238T1
- Authority
- CY
- Cyprus
- Prior art keywords
- combination
- histamine
- receptor
- antigonets
- acetylcholinesterase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με το συνδυασμό αντίστροφου αγωνιστή του υποδοχέα της ισταμίνης-3 και αναστολέα της ακετυλοχολινεστεράσης. Επίσης, η παρούσα εφεύρεση παρέχει αντίστροφο αγωνιστή του υποδοχέα της ισταμίνης-3 (H3R) ή το φαρμακευτικώς αποδεκτό άλας(άλατα) αυτού σε συνδυασμό με ή συμπληρωματικά με τον αναστολέα της ακετυλοχολινεστεράσης, και τη χρήση τους στη θεραπεία των γνωστικών διαταραχών. Η παρούσα εφεύρεση παρέχει περαιτέρω τη φαρμακευτική σύνθεση που περιέχει τον εν λόγω συνδυασμό.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028166 | 2016-08-18 | ||
| PCT/IB2017/054938 WO2018033847A1 (en) | 2016-08-18 | 2017-08-14 | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123238T1 true CY1123238T1 (el) | 2021-10-29 |
Family
ID=59887325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100725T CY1123238T1 (el) | 2016-08-18 | 2020-08-05 | Συνδυασμος antiστροφων αγωνιστων του υποδοχεα της ισταμινης-3 με αναστολεις της ακετυλοχολινεστερασης |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10603323B2 (el) |
| EP (1) | EP3500253B1 (el) |
| JP (1) | JP6734470B2 (el) |
| KR (1) | KR102039585B1 (el) |
| CN (1) | CN109640975B (el) |
| AU (1) | AU2017313427B2 (el) |
| BR (1) | BR112019002645A2 (el) |
| CA (1) | CA3033039C (el) |
| CY (1) | CY1123238T1 (el) |
| DK (1) | DK3500253T3 (el) |
| EA (1) | EA032957B1 (el) |
| ES (1) | ES2810983T3 (el) |
| HR (1) | HRP20201262T1 (el) |
| HU (1) | HUE052003T2 (el) |
| IL (1) | IL264406B (el) |
| LT (1) | LT3500253T (el) |
| MA (1) | MA45990B1 (el) |
| MD (1) | MD3500253T2 (el) |
| ME (1) | ME03812B (el) |
| MX (1) | MX2019001696A (el) |
| NZ (1) | NZ750150A (el) |
| PL (1) | PL3500253T3 (el) |
| PT (1) | PT3500253T (el) |
| RS (1) | RS60669B1 (el) |
| SG (1) | SG11201900681SA (el) |
| SI (1) | SI3500253T1 (el) |
| WO (1) | WO2018033847A1 (el) |
| ZA (1) | ZA201900467B (el) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52850A (fr) * | 2018-05-31 | 2021-04-21 | Suven Life Sciences Ltd | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120035183A (ko) * | 2009-06-10 | 2012-04-13 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| SI2694492T1 (sl) * | 2011-02-23 | 2015-11-30 | Suven Life Sciences Limited | Nove spojine kot ligandi histaminskega receptorja H3 |
| FR2974729B1 (fr) | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| SG11201601306QA (en) | 2013-09-09 | 2016-03-30 | Sanofi Sa | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
-
2017
- 2017-08-14 WO PCT/IB2017/054938 patent/WO2018033847A1/en active Search and Examination
- 2017-08-14 HU HUE17768234A patent/HUE052003T2/hu unknown
- 2017-08-14 PT PT177682341T patent/PT3500253T/pt unknown
- 2017-08-14 RS RS20200949A patent/RS60669B1/sr unknown
- 2017-08-14 MX MX2019001696A patent/MX2019001696A/es active IP Right Grant
- 2017-08-14 ES ES17768234T patent/ES2810983T3/es active Active
- 2017-08-14 SG SG11201900681SA patent/SG11201900681SA/en unknown
- 2017-08-14 CA CA3033039A patent/CA3033039C/en active Active
- 2017-08-14 PL PL17768234T patent/PL3500253T3/pl unknown
- 2017-08-14 ME MEP-2020-167A patent/ME03812B/me unknown
- 2017-08-14 LT LTEP17768234.1T patent/LT3500253T/lt unknown
- 2017-08-14 MD MDE20190714T patent/MD3500253T2/ro unknown
- 2017-08-14 BR BR112019002645A patent/BR112019002645A2/pt active Search and Examination
- 2017-08-14 EP EP17768234.1A patent/EP3500253B1/en active Active
- 2017-08-14 US US16/320,949 patent/US10603323B2/en active Active
- 2017-08-14 MA MA45990A patent/MA45990B1/fr unknown
- 2017-08-14 EA EA201990480A patent/EA032957B1/ru unknown
- 2017-08-14 KR KR1020197007056A patent/KR102039585B1/ko active IP Right Grant
- 2017-08-14 SI SI201730360T patent/SI3500253T1/sl unknown
- 2017-08-14 JP JP2019506640A patent/JP6734470B2/ja active Active
- 2017-08-14 DK DK17768234.1T patent/DK3500253T3/da active
- 2017-08-14 AU AU2017313427A patent/AU2017313427B2/en active Active
- 2017-08-14 CN CN201780049311.9A patent/CN109640975B/zh active Active
- 2017-08-14 NZ NZ750150A patent/NZ750150A/en unknown
-
2019
- 2019-01-22 IL IL264406A patent/IL264406B/en active IP Right Grant
- 2019-01-23 ZA ZA2019/00467A patent/ZA201900467B/en unknown
-
2020
- 2020-08-05 CY CY20201100725T patent/CY1123238T1/el unknown
- 2020-08-11 HR HRP20201262TT patent/HRP20201262T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1120662T1 (el) | Παραγωγα πυρρολαμιδιου υποκατεστημενου γλυοξαμιδιου και η χρηση αυτων ως φαρμακων για τη θεραπευτικη αντιμετωπιση της ηπατιτιδας β | |
| CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1120899T1 (el) | Παραγωγα 1,2,4-οξαδιαζολιου ως ανοσοτροποποιητες | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
| TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| CY1120535T1 (el) | Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη | |
| EA201892119A1 (ru) | Лекарственный препарат, полученный путем комбинирования агониста fxr и arb | |
| CY1123013T1 (el) | Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης | |
| CL2019001993A1 (es) | Inhibidores selectivos de jak1. | |
| UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| CY1123644T1 (el) | Τριπλος συνδυασμος καθαρων ανταγωνιστων του υποδοχεα 5-ητ6, αναστολεων της ακετυλοχολινεστερασης και του ανταγωνιστη του υποδοχεα nmda | |
| ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| TR201900680T4 (tr) | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. | |
| EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| CU20160166A7 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 |